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Purification and Properties of Bacterially Synthesized Human
Granulocyte-Macrophage Colony Stimulating Factor
By Antony W. Burgess, C. Glenn Begley, Gregory R. Johnson, Angel F. Lopez, D. James Williamson,
Jean Jacques Mermod, Richard J. Simpson, Albert Schmitz, and John F. DeLamarter
Human granulocyte-macrophage colony stimulating factor
(GM-CSF) has been synthesized in high yield using a
temperature inducible plasmid in Escherichia coil. The
human GM-CSF is readily isolated from the bacterial pro-
teins because of its differential solubility and chromato-
graphic properties. The bacterially synthesized form of the
human GM-CSF contains an extra methionine residue at
position i , but otherwise it is identical to the polypeptide
predicted from the cDNA sequence. The specific activity of
2.9 x i07 units/mg of protein for purified bacterially
synthesized human GM-CSF indicates that despite the lack
of glycosylation, the molecule is substantially in its native
conformation. This molecule stimulated the same number
and type of both seven- and i4-day human bone marrow
colonies as the CSFa preparation from human placental
conditioned medium. Human GM-CSF had no activity on
murine bone marrow or murine leukemic cells. There was
T HE IDENTIFICATION ofthe cDNA clone for murine
granulocyte-macrophage colony stimulating factor
(mGM-CSF)’ enabled the production of the biologically
active polypeptide by COS cells”2 and bacteria.3’4 The cDNA
mGM-CSF also led to the isolation of full-length cDNAs for
human GM-CSF5 (hGM-CSF) and confirmed the identity
of the human CSF cloned from a COS cell expression
library.6 The hGM-CSF expressed by COS cells79 appears
to encode all of the in vitro biological activities associated
with CSFa’#{176}prepared from human placental conditioned
medium” and conditioned medium from the U5637 cell
line)2 The COS cell-derived hGM-CSF stimulated the
proliferation and differentiation of granulocyte, macro-
phage, and eosinophil progenitor cells8’9 as well as the
function of neutrophils.’2 Thus, the simian-derived carbohy-
drate moiety does not appear to alter the cellular specificity
ofthe hGM-CSF.8’9 However, it is possible that a hGM-CSF
polypeptide with a simian, hamster, or yeast carbohydrate
moiety will be antigenic in vivo or that the different carbohy-
drate moiety will influence the in vivo distribution of the
GM-CSF. We have produced hGM-CSF in bacteria and
purified the polypeptide without any attached carbohydrate.
These studies define the conditions necessary for the prepa-
ration and purification of bacterially synthesized hGM-CSF,
the specific activity of the molecule, and its activities on
progenitor as well as mature cells. In part, these results
emphasize the continuing need to understand the interac-
tions between subsets of human bone marrow cells.’￿”
MATERIALS AND METHODS
Preparation and Purification ofBacterially Synthesized
Human GM-CSF
hGM-CSF cDNA was isolated from a library constructed using
mRNA from the human monocytic cell line U937’5 by screening
candidate clones with a nick-translated probe derived from the
coding sequences of mGM-CSF.3 The deduced amino acid sequence
of the U937 hGM-CSF was identical to hGM-CSF produced by the
leukemic cell line Mo(6) with the exception of the conservative
no detectable, direct stimulation of adult human erythroid
burst forming units (BFU-E) by the bacterially synthesized
human GM-CSF. Although impure preparations containing
native human GM-CSF (eg, human placental conditioned
medium) stimulated the formation of mixed colonies. even
in the presence of erythropoietin. the bacterially synthe-
sized human GM-CSF failed to stimulate the formation of
mixed colonies from adult human bone marrow cells. The
bacterially synthesized human GM-CSF increased N-
formyl-methionyl-leucyl-phenylalanine (FMLP)-induced
superoxide production and Iysozyme secretion. Antibody-
dependent cytotoxicity and phagocytosis by human neu-
trophils was stimulated by the bacterially synthesized
human GM-CSF and eosinophils were also activated in the
antibody-dependent cytotoxicity assay.
a 1986 by Grune & Stratton, Inc.
substitutions of a methionine by an isoleucine (amino acid 80 of the
mature protein) and a threonine by an isoleucine (amino acid 100 of
the mature protein). The amino acid for residue 100 of the mature
protein deduced from a genomic clone was also isoleucine.’6 These
differences between cDNAs and the genomic sequences may repre-
sent allelic variations. Sequences coding for the mature hGM-CSF
protein were placed in an Escherichia coli vector behind an inducible
promotor as previously described for the mGM-CSF gene.3 The
construction took advantage of the unique restriction endonuclease
site (Hga 1) located 58 nucleotides before the codon for the first
amino acid of the mature protein (alanine). An oligonucleotide
linker was synthesized to replace the deleted codons with the
addition of an amino-terminal methionine codon to initiate transla-
tion in the prokaryote host. This linker contained substitutions of
adenosine wherever retention of the native amino acid allowed.3 The
noncoding 3’ distal end of the cDNA was cleaved at the unique Bal 1
restriction endonuclease site and ligated to a similarly blunt-ended
site (Smal ) in the expression vector. Once introduced into a suitable
E. co/i host (LON-, HPTR-) the induction of hGM-CSF production
was initiated by temperature shift (28 #{176}C to 48 #{176}C). hGM-CSF
accumulated over four hours to 8% to 10% of the total cell protein.
Bacteria were harvested and GM-CSF extracted essentially as
described for mGM-CSF.3 In induced cells hGM-CSF accumulated
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in dense bodies which were collected by centrifugation following
breakage of the cells. After washing the pellet was resuspended in 6
mol/L guanidinium hydrochloride and 2 mmol/L /3-mercaptoetha-
not and chromatographed over G- 100 Sephadex in the same buffer.
The highly purified hGM-CSF fractions were collected and the
denaturant and reductant removed by slow dialysis against neutral
Tris buffer. The final purification step was gradient elution from a
reverse-phase support at pH 2.1 on an Ultrapore RPSC column
(4.6 x 7.5 cm) from Beckman, Santa Clara, CA.’7 The final purity
of the hGM-CSF was assessed by sodium dodecyl sulfate (SDS) gel
electrophoresis’8 and automated gas phase amino acid sequence
analysis.’9 The protein concentration for the specific activity calcu-
lation was determined by amino acid analysis.￿#{176}
Assays on Bacterially Synthesized Human GM-CSF
The purified hGM-CSF preparation (approximately 0.3 mg/mL
in acetonitrile [30%]: trifluoroacetic acid [0.1%): water [70%J) was
diluted 1:100 in 10% normal saline containing fetal calf serum
(FCS) (10%, vol/vol) and 0.1 mL of the diluted sample (or serial
dilutions thereof) was assayed in the l-mL semisolid bone marrow
cultures.
Human marrow cultures. Marrow and peripheral blood sam-
pies were obtained with the prior informed consent of patients
according to a protocol approved by the Ethics Committee of the
Royal Melbourne Hospital. Light density (p 1.070 g/cc) or nonad-
herent light density bone marrow cells (30,000) from patients with
no hematological disease were cultured in 35-mm Petri dishes using
1 mL of Dulbecco’s Modified Eagle’s Medium and a final concentra-
tion of 20% FCS and 0.3% agar.2’ Cultures were incubated for up to
14 days at 37 #{176}C in a fully humidified atmosphere of 10% CO2 in air.
For erythroid colony formation, 1-mL cultures containing 30,000
light density (< 1.070 g/cc) mononuclear or nonadherent mononu-
clear bone marrow cells in Iscove’s Modified Dulbecco’s Medium
and a final concentration of 25% FCS and 0.3% agar were estab-
lished. Cultures were incubated for 14 days in a fully humidified
atmosphere of 5% CO2 in air.
Colony formation (clones of more than 40 cells) was scored at 35 x
magnifications using a dissection microscope after seven or 14 days
of incubation. To determine the cellular composition of the resulting
colonies, intact cultures were fixed using 2.5% glutaraldehyde and
methanol and, after drying, were stained with Luxol Fast-Blue/
hematoxylin. Colony classification was performed at 400 x magnifi-
cations.
Units of colony stimulating activity were calculated from the
linear portion of the dose-response curve assigning 50 U/mL to the
concentration stimulating the formation of 50% maximal colony
numbers.
The human placental conditioned medium (HPCM) Stage II used
in these experiments was prepared as described previously.’0 The
semipurified CSFa and ￿3 fractions were obtained using phenyl-
Sepharose chromatography of medium conditioned by the human
bladder cancer cell line U5637, using methods described previous-
ly.22
Murine assays. Serial dilutions of bacterially synthesized hGM-
CSF samples (0. 1 mL) were added to agar cultures of 75,000 C57BL
adult marrow cells in FCS (20%) or 20,000 12-day CBA fetal liver
cells in cultures containing human plasma (20%). Control cultures
contained 400 units of purified mGM-CSF,’7 Multi-CSF,23 G-
CSF,24 M-CSF,25 or saline. Colony formation was scored after seven
days of incubation. To determine whether bacterially synthesized
hGM-CSF could initiate but not sustain colony formation by murine
hematopoietic cells, 400 units of Multi-CSF were added after two
days of incubation to replicate cultures of fetal liver cells and the
cultures scored after a total incubation period of seven days. After
scoring, cultures were stained with Luxol Fast-Blue/hematoxylin
and colonies classified according to cellular composition.
Microwell assays using the continuous hematopoietic cell lines
32D cl.32’ (kindly supplied by Dr J. Greenberger, Boston) and
FDC-Pl27 (kindly supplied by Dr TM. Dexter, Manchester,
England) were performed in microtiter trays using 200 cells per well
in 10 ￿L of Dulbecco’s Modified Eagle’s Medium with FCS (10%,
vol/vol). Serial dilutions of 5 ￿L of each test sample were added and
direct cell counts performed after 48 hours of incubation.
To determine whether bacterially synthesized hGM-CSF was
able to induce the differentiation of WEHI-3B(D￿) cells,￿ serial
dilutions of the hGM-CSF samples (0.1 mL) were added to agar
cultures of 300 WEHI-3B(D￿) cells. The percentage of colonies
exhibiting differentiation was determined after seven days of incuba-
tion.￿ Control cultures contained 0. 1 mL of serial dilutions of either
serum from C57BL mice injected three hours previously with 5 ￿ig
endotoxin￿#{176} or semipurified human CSF/3.’#{176}
Functional Activation ofMature Cells
Purification of human neutrophils and eosinophils. These cells
were obtained from the peripheral blood of healthy volunteers after
dextran sedimentation and centrifugation on a hypertonic gradient
of Metrizamide (Nyegaard, Oslo) as previously described.3’ The
purity was higher than 95% for neutrophils and higher than 92% for
eosinophils. The cells were resuspended in Eagle’s Minimal Essential
Medium supplemented with 10% FCS, 20 mmol/L HEPES buffer,
and antibiotics.
Antibody-dependent cell mediated cytotoxicity assay. ADCC
was performed as previously described.32 In brief, 40 ￿iL of 5’Cr-
labeled, trinitrophenyl (TNP)-coupled P815 cells (4 x I0￿) were
incubated with 24 ￿L of rabbit IgG anti-TNP (Rehovot, Israel), 80
￿iL of purified human neutrophils or eosinophils (1.3 x l0￿) as
effector cells, and 16 ￿iL of bacterially synthesized hGM-CSF for
two and one half hours at 37 #{176}C in V-bottom microtitre plates.
Percent cytotoxicity was calculated from the formula: (test -
control/total - control) x 100, where “control” was the 5’Cr
released by P8 15 cells in the presence of medium alone, and “total”
was the 5’Cr released by the addition of 5% Triton X-100.
Superoxide production. Purified neutrophils were incubated
with medium or different concentrations of bacterially synthesized
hGM-CSF for two hours at 37 #{176}C. After this, 150 ￿iL of cells (106)
were mixed with 100 zL freshly prepared cytochrome-C (Sigma, St
Louis, type VI, 12.4 mg/mL), 100 ML N-formyl-methionyl-leucyl-
phenylalanine (FMLP) (10’ mol/L) and made up to 1 mL with
medium. The mixtures were then incubated at 37 #{176}C for five
minutes, after which the cells were rapidly cooled, centrifuged at
4 #{176}C, and the supernatants transferred to plastic disposable cuvettes.
Superoxide production was measured by the reduction of cyto-
chrome-C33 using an extinction coefficient of 21 . I mmol/L I
The medium used throughout these assays was RPMI (free of
phenol red) containing 2% FCS. In control experiments, bacterially
synthesized hGM-CSF did not reduce cytochrome-C in the absence
of cells, and superoxide dismutase (Sigma) completely abolished the
reduction of cytochrome-C. The results are expressed as the means
of triplicate determinations ± 1 standard deviation.
Phagocytosis assay. This assay measured the phagocytosis of
serum-opsonized baker’s yeast and was performed as described.9 In
brief, 100 ￿uL purified neutrophils (2 x 107/mL) were incubated
with 250 ￿oL baker’s yeast, 100 ￿L diluted fresh autologous serum
and 50 ￿L bacterially synthesized hGM-CSF or medium with FCS
for one hour at 37 #{176}C After this, the cells were centrifuged at 4 #{176}C,
resuspended in 50 ￿tL of cold PBS and smeared onto a slide. When
eosinophils were tested, this assay was scaled down because of the
relatively low numbers of cosinophils routinely obtained. The vol-
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Fig 1 . Reversed phase high-performance liquid chromatogra-
phy purification of bacterially synthesized human GM-CSF.
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umes were 20 ￿oL of cells (107/mL), 50 ML of baker’s yeast, 20 ￿iL of
freshly obtained human serum and 10 ￿tL of bacterially synthesized
hGM-CSF or medium. After incubation, cytocentrifuge prepara-
tions were made. Slides were fixed in methanol and stained with
Giemsa before being examined for the number of cells showing
different numbers of phagocytosed yeast. The data are expressed as
percentages after counting a minimum of 200 cells per slide.
Degranulation assay. This was carried out as previously
described.35 Briefly, purified neutrophils (5 x 106/mL) pretreated
with cytochalasin-B (Sigma) were incubated with different stimuli
for 15 minutes at 37 #{176}C. To these mixtures different concentrations
of FMLP (Sigma) were added and the cells incubated a further 30
minutes at 37 #{176}C. After incubation the cells were centrifuged and the
released lysozyme assayed against Micrococcus lysodeikticus (Sig-
ma). The optical density at 450 nm was measured at ten-second
intervals for three minutes. Triplicate determinations (every ten
seconds) were made and the amount of lysozyme released was
calculated from a standard curve generated by egg white lysozyme
(Sigma). Maximum values were obtained by using supernatants
from neutrophils lysed with Triton X-lOO.
RESULTS AND DISCUSSION
Induction and Purification ofBacterially Synthesized
Human GM-CSF
Recombinant hGM-CSF was produced in E. coli under
the regulation of a heat-inducible promoter. After GM-CSF
synthesis was induced by raising the culture temperature, the
protein accumulated in aggregates as dense bodies within the
cells. Following weakening of the cell walls by lysozyme
treatment, cells were disrupted in a French pressure cell. The
aggregates were collected by centrifugation and resuspended
in 6 mol/L urea. hGM-CSF was initially purified from the
solution by chromatography over Sephadex GiOO. Aliquots
(2 to 5 mL) of the low-molecular weight fraction from the
gel filtration containing GM-CSF were diluted with an equal
volume of aqueous trifluoroacetic acid (0. 1 5%, vol/vol) and
loaded onto a reversed-phase Ultrapore RPSC column equil-
ibrated with aqueous trifluoroacetic acid (0.15%, vol/vol).
Several proteins were eluted from the column (Fig 1), but the
earliest eluting material was not associated with biological
activity. SDS-polyacrylamide gel analysis of the column
fractions (Fig 2) indicated that the 16,000-dalton protein
associated with the biologic activity was pure. Amino acid
sequence analysis of 200 pmoles of the purified hGM-CSF
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Fig 2. Electrophoretic analysis of purified bacterially synthe-
sized human GM-CSF.
yielded a single amino acid at each cycle; the first residue
detected was methionine, and the next 16 cycles yielded the
sequence expected from the nucleotide sequence.6 Thus, this
product is different from the natural molecule in that not
only is the carbohydrate moiety missing, but there is also an
N-terminal methionine which is not removed during synthe-
sis. The results of the quantitative amino acid analysis of the
purified bacterially synthesized hGM-CSF were in excellent
agreement with the composition predicted from the nucleo-
tide sequence. The optical density at pH 2.1 in the presence
of acetonitrile (30%, vol/vol), together with the amino acid
analysis yielded a molar extinction coefficient of 2 x i0￿
moles’ cm’. Attempts to determine a precise specific
activity for the purified bacterially synthesized hGM-CSF
are complicated by the wide variation in sensitivity of
different bone marrow samples and variations in the fre-
quency of colony-forming cells for different human bone
marrow samples. The standard assays were performed using
between 30,000 and 50,000 bone marrow cells per milliliter.
Eight separate bone marrows stimulated by the purified
bacterially synthesized hGM-CSF yielded an average spe-
cific activity of 2.9 ± 1.9 x i0￿ U/mg of protein after seven
days in culture. The same four samples yielded a specific
activity of 2.9 ± 0.7 x i0￿ U/mg of protein after 14 days in
culture. The ratio of day-7 to day-i4 colonies was dependent
on the bone marrow sample and varied from 0.3 to 1.6. In
general, impure samples of hGM-CSF (eg, human placental
conditioned medium or bladder carcinoma conditioned
medium) contained a mixture of both hGM-CSF (CSFa)
and hGM-CSF (CSF$). The CSFI3 preparation preferen-
tially stimulates colony formation at day 7; thus, the ratio of
the number of colonies at day 7 to day 14 (approximately
three) tends to be considerably higher than for GM-CSF and
the CSFa preparation. Similarly, a mixture of the bacterially
synthesized GM-CSF and the CSFI3 preparation generally
stimulates more day-7 colonies than either stimulus by itself.
Each molecule preferentially stimulates a defined subset of
GM-progenitor cells. After 14 days in culture the bacterially
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From rHGM-
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Fig 3. Effect of GM-CSF on colony growth for eight normal
human bone marrow samples. (A) Day 7; (B) Day 14. The results
are presented as the mean and standard deviations. The results of
assays with optimal concentrations of CSFa and CSFfi prepared
from human placental conditioned medium are also displayed.
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synthesized hGM-CSF stimulated as many colonies as prep-
arations of CSFcr’#{176} from human placental conditioned
media.”
Our method of preparation and purification indicates that
the bacterially synthesized hGM-CSF is stable in 6 mol/L
urea, as well as at pH 2. 1 in the presence of 40% acetonitrile.
Indeed, at low pH the bacterially synthesized hGM-CSF
appears to retain its full biologic activity indefinitely. How-
ever, initial attempts to store this hGM-CSF at neutral pH in
the absence of urea have led to precipitation of the mole-
cule.
Concentration Dependence of Colony Formation
The purified hGM-CSF was titrated and assayed on eight
separate bone marrow aspirates: both the seven-day (Fig
3A) and 14-day (Fig 3 B) cultures indicated that maximal
stimulation of colony formation was achieved at concentra-
tions of 500 pmol/L or greater. Half-maximal stimulation
occurred between 60 pmol/L and 120 pmol/L and the
minimum detectable hGM-CSF concentration using the
semisolid agar assay was 10 pmol/L for both time points.
The direct action of bacterially synthesized hGM-CSF on
human colony forming cells was examined by transfer of
day-5 clones to plates containing the bacterially synthesized
hGM-CSF, human placental conditioned medium, or saline
(Fig 4). The bacterially synthesized hGM-CSF continued to
stimulate colony growth and GM-CSF is undoubtedly one of
the active hematopoietic growth factors in the HPCM.
Morphology of Colonies
In two separate experiments, the types of colonies stimu-
lated by the bacterially synthesized hGM-CSF have been
compared to the colony types obtained with unfractionated
HPCM, CSFa, and CSFL3 (Table 1 ). The bacterially synthe-
sized hGM-CSF stimulated pure neutrophil (G), macro-
phage (M) and eosinophil (Eo) colonies as well as mixed
granulocyte-macrophage colonies. At day 7 all preparations
of CSF stimulated mainly granulocytic colonies. However,
the bacterially synthesized hGM-CSF and CSFa also stimu-
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Fig 4. Growth of colonies after transfer of Day 5 human bone
marrow colonies to recipient plates with either bacterially synthe-
sized hGM-CSF, human placental conditioned medium (HPCM). or
saline. The solid circles represent colonies composed of neutro-
phils. macrophages. or both. and the open circles represent the
eosinophil colonies.
lated a small proportion of Eo colonies. As expected, for both
HPCM and CSFa the proportions of pure M and pure Eo
colonies were increased at 14 days. Thus, the bacterially
synthesized hGM-CSF stimulated a similar range of colonies
to the CSFa.
The bacterially synthesized hGM-CSF was used in an
attempt to stimulate the hematopoietic progenitor cells in
murine bone marrow. Even at a concentration of 2 nmol/L
no colonies or clusters were observed after seven days in
culture. The hGM-CSF did not enhance the survival of
multi-CSF-responsive progenitor cells in the delayed addi-
tion assay. Similarly, there was no effect of this hGM-CSF
on several murine cell lines which were known to respond to
murine hematopoietic growth factors: WEHI-3BD￿ (G-
CSF-responsive) did not differentiate in response to hGM-
CSF, FDCPI (GM-CSF- or Multi-CSF-dependent) and
32D cells (Multi-CSF-dependent) did not proliferate in the
presence of hGM-CSF (data not shown).
Effect ofBacterially Synthesized Human GM-CSF on
Erythroid Progenitor Cells
The colony types stimulated by human tissue-derived
conditioned media (eg, human placental conditioned
medium, [HPCM]) have been studied extensively using a
range of partially purified hematopoietic progenitor cells.36’37
Studies by Sieff et al with a hGM-CSF partially purified
from transfected COS cell conditioned medium indicated
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Table 1 . Morpholog y of Human Bone Marrow Cob nies Stimulated by Bacterially ynthesized hGM-CSF
Incubation
Time
Experiment
Number Stimulus
Number of
Colonies’
Colony Type (%)
G GM M Eos
7days 1
2
Saline
HPCM
hGM-CSF (recombinant)
CSFa
CSF$
Saline
HPCM
hGM-CSF (recombinant)
CSFa
CSFfl
0
275
230
232
278
0
146
98
98
149
-
84
83
83
82
-
64
58
56
64
- -
0 16
0 1 1
0 17
0 18
- -
2 34
3 36
8 32
5 31
-
0
6
0
0
-
0
3
4
0
l4days 1
2
Saline
HPCM
hGM-CSF (recombinant)
CSFa
CSF￿
Saline
HPCM
hGM-CSF (recombinant)
CSFa
CSF/3
0
98
95
93
31
3
87
89
85
30
-
42
40
52
72
0
31
23
24
67
- -
6 39
3 42
1 38
0 28
0 100
13 50
12 52
13 49
12 21
-
13
15
9
0
0
6
13
14
0
C 3 x 1O￿ light density nonadherent human bone marrow cells were cultured in 1 mL of semisolid agar and examined after seven and 14 days. The
agar cultures were fixed and stained and the colonies analyzed to determine the proportion of G. neutrophil; M. macrophage; GM, neutrophil-macrophage
and EOS, eosinophil colonies.
some potentiating effect of the GM-CSF on BFU-E prolifer-
ation.38 Similarly, their results with highly purified fetal
BFU-E suggested that pure hGM-CSF stimulates the prolif-
eration and differentiation of these cells. However, the initial
results with purified mGM-CSF on murine fetal liver pro-
genitor cells39 indicated that only a subset of the fetal BFU-E
appeared to be responsive to GM-CSF and the proportion of
adult BFU-E responsive to GM-CSF appears to be quite
small.
In a report of experiments with the COS cell-derived
recombinant hGM-CSF and human fetal progenitor cells,￿#{176}
it was noted that even though the BFU-E represented 30% of
the cell population when the culture cell density was below
100 cells/mL no colonies developed in the presence of
GM-CSF. It is possible that the GM-CSF stimulated acces-
sory cells to produce BFU-E stimulating factors. Initially, we
attempted to detect the effect of the bacterially synthesized
GM-CSF on BFU-E in mononuclear and nonadherent mono-
nuclear cells from human bone marrow cells (Tables 2 and
3).
The light density mononuclear cells from human bone
marrow did not produce erythroid colonies in the absence of
erythropoietin (Table 2). In the presence of erythropoietin,
erythroid colonies developed. Addition of a source of CSF
(HPCM) did not change the frequency oferythroid colonies.
However, the neutrophil-, eosinophil-, and macrophage-
containing colonies appeared as expected. Identical effects
were observed with the bacterially synthesized human GM-
CSF (at both 2.5 nmol/L and 50 nmol/L). When the
addition of erythropoietin was delayed for three to four days,
there was a slight decrease in erythroid colony numbers but
neither HPCM nor the bacterially synthesized hGM-CSF
influenced the survival of these erythroid progenitors.
Table 2. No Effect of Bacterially Synthesized hGM-CSF on
Erythroid Colony Formation From Mononuclear
Human Bone Marrow Cells
Day of Epot
Nu mber of CoIonies￿
Pure Mixed Non-
Stimulus’ Addition Erythroid Erythroid erythroid
- - 0 0 0
-
HPCM
0
0
24±5
25±2
0
0
16±3
98±5
HPCM - 0 0 110±3
hGM-CSF (2.5 nmol/L) - 0 0 1 1 ± 12
hGM-CSF (2.5 nmol/L) 0 20 ± 8 0 102 ± 4
hGM-CSF (50 nmol/L) - 0 0 124 ± 1 1
hGM-CSF (50 nmol/L) 0 13 ± 5 0 104 ± 1 1
- 3 17±6 0 16±5
- 4 13±5 0 17±4
HPCM 3 16±1 0 117±5
HPCM 4 15 ± 6 0 121 ± 13
hGM-CSF (2.5 nmol/L) 3 2 1 ± 8 0 87 ± 9
hGM-CSF (2.5 nmol/L) 4 21 ± 4 0 65 ± 10
hGM-CSF (50 nmol/L) 3 14 ± 2 0 99 ± 9
hGM-CSF (50 nmol/L) 4 12 ± 1 0 104 ± 15
-. Epo not added.
#{149}The stimulus HPCM (0. 1 mL) or the diluted, purified bacterially
synthesized hGM-CSF (0. 1 mL) was added at the start of the 14-day
cultures of 3 x 10￿ light density bone marrow cells in the standard soft
agar assay.2’
tPartially purified erythropoietin (Epo) was added to a final concentra-
tion of 1 .5 U/mL either at the start of the cultures (day 0) or at three or
four days after initiating the assay.
￿For all assays three replicate plates were scored after 14 days. The
table entries represent the mean ± SD.
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Table 3. No Effect of Bacterially Synthesized hGM-CSF on
Erythroid Colony Formation from Nonadherent
Mononuclear Human Bone Marrow Cells
DayofEpo
Number of Colonies
Pure Mixed Non-
Stussulus Addition Erythroid ErythrOid eryshrold
-
-
HPCM
-
0
0
0 0 14±2
38±4 0 13±3
62 ± 4 1 ± 1 140 ± 1 1
HPCM - 0 0 151±10
hGM-CSF (2.5 nmol/L) - 0 0 97 ± 6
hGM-CSF (2.5 nmol/L) 0 22 ± 1 0 97 ± 1
hGM-CSF (50 nmol/L) - 0 0 227 ± 6
hGM-CSF (50 nmol/L) 0 26 ± 1 0 2 17 ± 5
-
-
3
4
12±1 0 20±6
8±2 0 17±7
HPCM 3 31 ± 7 1 ± 1 95 ± 2
HPCM 4 31±5 0 90±3
hGM-CSF (2.5 nmol/L) 3 1 1 ± 2 0 104 ± 6
hGM-CSF (2.5 nmol/L) 4 9 ± 2 0 105 ± 6
hGM-CSF (50 nmol/L) 3 1 6 ± 1 0 19 1 ± 2
hGM-CSF (50 nmol/L) 4 4 ± 1 0 206 ± 1 1
#{149}See footnote to Table 2 for technic al details of these experiments.
After removing the adherent cells, HPCM but not the
bacterially synthesized hGM-CSF increased the cloning
efficiency of the erythroid progenitor cells (Table 3). When
the adherent cells are removed, a subset of the erythroid
progenitors appears to be stimulated by HPCM. Even when
the erythropoietin is added three or four days after the
initiation of the cultures with HPCM this synergistic effect
of HPCM can be observed (Table 3). Again, approximately
half the erythroid colonies appear to be stimulated by a
molecule present in human placental conditioned medium. It
is unlikely that GM-CSF is related to this phenomenon, as
the bacterially synthesized hGM-CSF did not modulate the
number of I 4-day erythroid colonies.
When both erythropoietin and hGM-CSF were present,
their effects appeared to be independent. No extra erythroid
colonies were observed compared to the cultures stimulated
with erythropoietin alone. In contrast, unfractionated
HPCM consistently increased (two- to fourfold) the number
of erythroid colonies developing from the nonadherent light
density mononuclear bone marrow cells. Mixed erythroid
colonies4’ were only observed in the presence of the unfrac-
tionated HPCM. Neither the bacterially synthesized GM-
CSF, the erythropoietin, nor the mixture of both were able to
stimulate human mixed colonies. At concentrations greater
than 500 pmol/L, the bacterially synthesized GM-CSF
stimulated the same range of nonerythroid colonies as the
optimum concentration of human placental conditioned
medium.
The lack oferythroid (BFU-E) potentiation by hGM-CSF
could be due to the presence of accessory cells which suppress
the GM-CSF-responsive BFU-E. However, the previously
reported effects of GM-CSF may also be indirect (ie, via a
GM-CSF-responsive cell which produces an erythroid fac-
tor). Understanding the interactions between the different
cells controlling human erythropoiesis will require a detailed
analysis of the proliferation of single cells and subsequent
cell-mixing experiments.
Action ofBacterially Synthesized hGM-CSF on Mature
Hematopoietic Cells
As well as stimulating the proliferation of the myeloid
progenitor cells, the hGM-CSF purified from the Mo cell
line is able to stimulate some of the functions of mature
neutrophils8’9”2 and eosinophils.2#{176} We have measured the
effect of the bacterially synthesized GM-CSF on four
parameters of granulocyte function: superoxide (02)
production,33’34 phagocytosis,9 lysozyme secretion,35 and anti-
body-dependent cell-mediated cytotoxicity.32 At concentra-
tions of hGM-CSF above 10 pmol/L both purified neutro-
phils and eosinophils were stimulated maximally to kill
tumor target cells, and stimulation of killing was still detect-
able at 1 pmol/L (Fig 5). The concentration dependence of
neutrophil and eosinophil activation was very similar (Fig 5).
A similar concentration-dependent effect on neutrophil func-
tion was obtained by Weisbart et al5 for the inhibition of
neutrophil migration using either recombinant hGM-CSF
produced by transfected monkey COS cells or the hGM-CSF
purified from the Mo cell line. Thus, our results show that
hGM-CSF does not require carbohydrate moieties for its
action in vitro.
COS cell-derived hGM-CSF has been previously found to
stimulate phagocytosis.9 A comparison of the effects of E.
co/i-synthesized hGM-CSF on neutrophil phagocytosis of
yeast organisms in the presence or absence of serum is
displayed in Fig 6. In the presence of fresh human serum, the
bacterially synthesized hGM-CSF (4 nmol/L) activated
large numbers of neutrophils to phagocytose several yeast
particles (Fig 6). Heating of human serum for 30 minutes at
56 #{176}C abrogated the GM-CSF stimulation of neutrophils to
phagocytose heat-killed yeast (data not shown), suggesting
that complement is the opsonic factor present in human
serum, and that the stimulation by hGM-CSF is dependent
on the presence of this opsonin. There was a 50% increase in
the number of neutrophils which phagocytosed the heat-
killed yeast (Fig 6).
The response of neutrophils to bacterial products also
appears to be stimulated by hGM-CSF. The secretion of
lysozyme by neutrophils was dependent on the presence of
chemotactic agents (Table 4). In the absence of a chemotac-
tic peptide such as FMLP,42 there was no activation of
lysozyme secretion. However, preincubation of neutrophils
with the bacterially synthesized hGM-CSF enhanced the
FMLP-induced release of lysozyme from purified neutro-
phils by 60% (Table 4). At low concentrations of the
chemotactic peptide (108 mol/L) the hGM-CSF was more
.￿ ￿ 30
￿ 20
>‘￿
￿ .5 10
0” 1O-￿￿ 10￿” 10￿” 10￿￿ 10-b
Concentration of human GM-CSF (Mt
Fig 5. Effect of GM-CSF concentration on the ability of human
neutrophils or eosinophils to kill antibody-coated P81 5 mastocy-
toma cells.
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Fig 6. Effect of GM-CSF (4 nmol/L) on the ability of human
neutrophils to phagocytose yeast.
effective than lipopolysaccharide.43 Bacterially synthesized
hGM-CSF also enhanced FMLP-mediated stimulation of
superoxide production by human neutrophils (Fig 7). In the
absence of hGM-CSF and FMLP, superoxide production by
human neutrophils was not detectable. The chemotactic
peptide by itself induced 02 production to 1.3 nmoles/
min/ 106 cells. In the absence of FMLP, hGM-CSF had little
or no effect on 02 production (Fig 7). However, preincuba-
tion of neutrophils with GM-CSF followed by FMLP
increased the amount of 02 production sevenfold over the
level induced by FMLP alone. The interaction between
FMLP and GM-CSF was concentration dependent: the
maximal rate of O2 production was achieved at 200 pmol/
L, but the synergism was still evident when the hGM-CSF
concentration was 10 pmol/L (Fig 7).
Thus, GM-CSF is capable of enhancing at least three
separate systems in human neutrophils: the release of both
lysozyme and 02 (upon stimulation with FMLP), phagocy-
tosis of yeast (complement-mediated), and killing of tumor
target cells (antibody-dependent).￿ In its ability to activate
mature neutrophils, this bacterially-synthesized hGM-CSF
behaves very similarly to the recombinant hGM-CSF pro-
duced by transfected monkey COS cells (ref 9, and Lopez et
al, in preparation).
We have demonstrated the action of purified, bacterially
synthesized hGM-CSF on a range of hematopoietic progeni-
tor and mature cells. This GM-CSF has a specific activity in
the same range as the recombinant GM-CSF purified from
medium conditioned by Mo cells38 or the medium from COS
cells transfected with cDNA for hGM-CSF’2 (Table 5).
Thus, neither the addition of the extra N-terminal methio-
nine residue, nor the absence of carbohydrate appear to
affect the in vitro activity of hGM-CSF. The detailed
morphological distribution of the colonies stimulated by both
the E. co/i-synthesized and COS cell-stimulated hGM-CSF
Table 4. Effect of Bacterially Synthesized hGM-CSF on
Lysozyme Release by Neutrophils
.
De￿anulating
Stimulus
Lysozym e Secretion Following Preinc
with hGM-CSF (pmol/L)t
ubation
Nil 30 120 300
Nil 0±1 0±0 0±0 0±1
FMLP i0￿ mol/L 27 ± 4 35 ± 1 70 ± 2 66 ± 5
FMLP lO8mol/L 106 ± 6 122 ± 1 147 ± 8 150 ± 8
Lysozyme secretion expressed as the average U/mL/min/ 10￿ neutro-
phils ± SD (for three replicate cultures).
02 04 06 08 10 12
Concentration of human GM-CSF
nM)
Fig 7. Enhancement by human GM-CSF of FMLP-induced
superoxide production by human neutrophils.
varies considerably and is dependent on the specific bone
marrow being assayed. However, both forms stimulate pre-
dominantly neutrophilic granulocyte colonies at day 7 (Table
5), and by day 14 most of the colonies contain macrophages.
There is a similar increase in the proportion of eosinophil
colonies with both GM-CSFs by day 14 (Table 5).
Our attempts to show the direct effects of hGM-CSF on
erythroid progenitor cells (ie, BFU-E) have been unsuccess-
ful. Despite the availability of a pure stimulus such as the
bacterially synthesized hGM-CSF, the purity ofour hemato-
poietic progenitor cells has been insufficient to prove that the
hGM-CSF acts directly on progenitors of the erythroid
series. At least one study using COS cell-derived recombi-
Table 5. Comparison of E. colt-Derived and
COS Cell-Derived hGM-CSF
Property
hGM-CSF
E. co/i-Derived COS Cell-Derived
Apparent molecular
weights 16,000 19,000-22.000
Specific Activity (U/mgi
1 o￿ bone marrow
cells) 1 x i07 1 x 10#{176}-S x i0￿
Morphology of myeloid
colonies
(%)4
Day 7 Day 14 Day 8 Day 14
G
GM
M
Eo
70 31 G 70 8
4 8 GM 20 16
24 47 M 5 51
2 14 Eo 5 25
BFU-E Responsiveness No effect (a) Stimulated
“directly”
(b) No effect
(c) Inhibitory in the
presence of
erythroid poten-
tiating activity
Responsive mature cells G, Eo G, Eo, and mono-
cytes45
Abbreviations: G, granulocytes; GM, granulocyte-macrophages; M,
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nant hGM-CSF also reported that there was no effect on
BFU-E, although in the presence of erythroid potentiating
activity and erythropoietin, the human GM-CSF appeared
to inhibit BFU-E.45 Others appear to have shown effects of
COS cell-derived hGM-CSF on highly purified BFU-E.’#{176}It
will be necessary to study the effects of pure hGM-CSF on
single BFU-E before we can be sure that the hGM-CSF has
a direct effect on erythropoiesis.
The availability of E. co/i-synthesized hGM-CSF with
essentially identical biologic properties to natural hGM-CSF
will provide sufficient quantities of this molecule for clinical
testing. The absence of any foreign carbohydrate moiety
should reduce problems with immunologic neutralization
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